|
gptkbp:instance_of
|
gptkb:Ophthalmology
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
|
gptkbp:average_temperature
|
room temperature
|
|
gptkbp:class
|
gptkb:immunotherapy
anti-inflammatory
|
|
gptkbp:clinical_trial
|
Phase III
DEWS study
RESTORE study
SYSTANE study
|
|
gptkbp:clinical_use
|
long-term treatment
|
|
gptkbp:condition
|
gptkb:Sjogren's_syndrome
allergic conjunctivitis
eyelid inflammation
|
|
gptkbp:contraindication
|
hypersensitivity to cyclosporine
|
|
gptkbp:dosage_form
|
emulsion
|
|
gptkbp:form
|
gptkb:cream
|
|
gptkbp:formulation
|
0.05% solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Restasis
|
|
gptkbp:ingredients
|
gptkb:cyclosporine_A
|
|
gptkbp:invention
|
gptkb:2022
|
|
gptkbp:manufacturer
|
gptkb:Allergan
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
increases tear production
|
|
gptkbp:packaging
|
single-use vials
|
|
gptkbp:patient_education
|
report any severe eye pain
avoid touching the dropper tip
wait 15 minutes before using other eye drops
|
|
gptkbp:patient_population
|
adults
children over 16 years
|
|
gptkbp:pharmacokinetics
|
local action
minimal systemic absorption
|
|
gptkbp:previous_name
|
no
|
|
gptkbp:price
|
approximately $500 per month
|
|
gptkbp:provides_guidance_on
|
gptkb:American_Academy_of_Ophthalmology
gptkb:European_Society_of_Ophthalmology
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:route_of_administration
|
topical
|
|
gptkbp:service_frequency
|
twice daily
|
|
gptkbp:side_effect
|
headache
itching
eye pain
foreign body sensation
redness of the eye
burning sensation in the eyes
discharge from the eye
dryness of the eye
|
|
gptkbp:trade
|
gptkb:Restasis
|
|
gptkbp:used_for
|
treating dry eye disease
|
|
gptkbp:bfsParent
|
gptkb:Allergan
|
|
gptkbp:bfsLayer
|
5
|